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Review
Article
Fibroblast Growth Factor 21 Mimetics for Treating 
Atherosclerosis
Kelvin H. M. Kwok1,2, Karen S. L. Lam1,2,3
1State Key Laboratory of Pharmaceutical Biotechnology, 2Department of Medicine, 3Research Centre for Heart, Brain, Hormone 
and Healthy Aging, The University of Hong Kong, Hong Kong
Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose 
uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose 
tissue. Emerging evidence shows a strong correlation between circulating FGF21 levels and the incidence and severity of atheroscle-
rosis. Animal studies have demonstrated a beneficial role of FGF21 in protecting against aberrant lipid profile, while recent develop-
ment in FGF21 mimetics has provided further insight into the lipid-lowering effects of FGF21 signaling. The present review sum-
marizes the physiological roles of FGF21, and discusses major breakthroughs and limitations of FGF21 mimetic-based therapeutic 
strategies for treating atherosclerosis.
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INTRODUCTION
Fibroblast growth factor 21 (FGF21) is an atypical member of 
the FGF superfamily that exerts pleiotropic effects on metabolic 
regulation [1]. Since FGF21 lacks the classic heparin-binding 
domain which is crucial for binding to cognate FGF receptors 
(FGFRs) [1], it requires the presence of a co-receptor, β-klotho, 
for effective receptor docking [2]. FGF21 is able to enter the 
circulation without non-specific binding to heparin sulphate 
proteoglycan and function as an endocrine factor in target or-
gans [1]. While there is mounting evidence showing the benefi-
cial effects of FGF21 on obesity and diabetes in humans and an-
imals [3,4], the physiological roles of FGF21 in atherosclerosis 
is gaining increasing attention only recently. This review sum-
marizes the role of FGF21 in atherosclerosis development, and 
highlights some recent findings on the therapeutic potential of 
FGF21 mimetics in treating atherosclerosis.
SIGNALING CASCADE OF FGF21
FGFRs are a family of single transmembrane protein consisting 
of an extracellular ligand-binding domain and an intracellular 
tyrosine kinase domain [1]. FGFR1c, a splice variant of the 
FGFR1 subtype, is responsible for the majority of the physio-
logical actions of FGF21 in the presence of β-klotho [5,6]. Al-
though FGFRs are widely expressed in the body, the expression 
of β-klotho is largely restricted to the liver, pancreas, and white 
and brown adipose tissue [7]; hence, giving rise to tissue speci-
ficity of FGF21 signaling. The direct binding between FGF21 
and FGFR/β-klotho leads to the phosphorylation of downstream 
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targets, including FGFR substrate 2 (FRS2), protein kinase B 
(Akt), sirtuin 1 (Sirt1), glycogen synthase kinase 3 (GSK3), 
Raf, and signal transducer and activator of transcription 3 
(STAT3), as well as a rapid rise in intracellular calcium [8,9], 
which subsequently promote the expression of target genes in-
volved in glucose and lipid metabolism [10].
PHYSIOLOGICAL ROLE OF FGF21
FGF21 serves as a major sensor for metabolic stresses, includ-
ing starvation, overfeeding, and cold exposure [11]. Its expres-
sion is markedly induced by peroxisome proliferator-activated 
receptor α (PPARα) in the liver during fasting [12], from where 
it promotes hepatic gluconeogenesis via a hypothalamus-pitu-
itary-adrenal axis to maintain glucose homeostasis [13]. In adi-
pocytes, FGF21 forms a feed-forward regulatory loop with 
PPARγ [14], a key regulator of adipogenesis [15], whereby 
PPARγ promotes the transcription of FGF21, and FGF21 sus-
tains PPARγ activity by preventing its sumoylation [16]. FGF21 
is responsible for the thiazolidinedione-mediated glucose uptake 
and adipogenesis, and the consequent improvement in insulin 
sensitivity and lipid storage [16]. FGF21 increases glucose up-
take by up-regulating the expression of glucose transporter 1 
(GLUT1) through the synergistic actions of serum response fac-
tor (SRF) and Ets-like protein 1 (Elk-1) [17]. In addition, it di-
rectly increases the expression and secretion of adiponectin, a 
potent insulin-sensitizing adipokine, which in turn contributes 
to alleviation of obesity-associated hyperglycemia, insulin resis-
tance and hepatic steatosis [18]. Under cold conditions, the ex-
pression of FGF21 is up-regulated in both white and brown adi-
pose tissues [19], where it drives adaptive thermogenesis, at 
least in part through increasing the protein levels of PPARγ co-
activator 1α (PGC-1α), a major regulator of the browning ma-
chinery [20].
ANTI-DYSLIPIDEMIC AND ANTI-
ATHEROSCLEROTIC PROPERTIES OF 
FGF21
Recent clinical studies have provided mounting evidence for a 
critical role of FGF21 in the development of atherosclerosis-re-
lated diseases (Tables 1, 2). Elevated serum FGF21 levels is in-
dependently associated with total cardiovascular events [21], 
coronary heart disease [22], atherosclerosis in carotid arteries 
[23,24] and in the extremities [25], and arterial stiffness [26]. It 
is also predictive of cardiovascular events and mortality in type 
2 diabetic patients [27]. Moreover, FGF21 strongly correlated 
with a number of independent risk factors for atherosclerosis, 
including obesity [28], type 2 diabetes [29,30], hypertension 
[31], non-alcoholic fatty liver disease [32-34], diabetic nephrop-
athy [35], chronic kidney disease [36], and dyslipidemia [22,37]. 
In particular, serum FGF21 correlated positively with total cho-
lesterol and triglyceride [37], and negatively with high density 
lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (apoA1) 
[22]. Genetic association studies also identified a single nucleo-
tide polymorphism in FGFR2 gene showing replicable associa-
Table 1. Associations between FGF21 and Atherosclerotic Risk Factors
Risk factor Result Reference
Obesity BMI correlated positively with serum FGF21 [28]
T2DM Elevated plasma FGF21 [29]
Elevated plasma FGF21 predicted diabetes development [30]
Hypertension Independently associated with elevated serum FGF21 [31]
Dyslipidaemia Serum FGF21 correlated positively with serum TG [37]
Serum FGF21 correlated positively with total cholesterol [37]
Serum FGF21 correlated negatively with HDL-C [22]
rs2071616 SNP in FGFR2 gene was associated with LDL-C [38]
NAFLD Elevated hepatic FGF21 expression [32]
Elevated serum FGF21 [33,34]
Diabetic nephropathy Elevated baseline serum FGF21 was associated with and predicted decline of renal function [35]
CKD Elevated serum FGF21 [36]
FGF21, fibroblast growth factor 21; BMI, body mass index; T2DM, type 2 diabetes mellitus; TG, triglyceride; HDL-C, high density lipoprotein choles-
terol; SNP, single nucleotide polymorphism; FGFR2, FGF receptor 2; LDL-C, low density lipoprotein cholesterol; NAFLD, non-alcohol fatty liver dis-
ease; CKD, chronic kidney disease. 
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tion with low density lipoprotein cholesterol (LDL-C) [38].
The lipid-lowering properties of FGF21 in atherosclerosis 
have been demonstrated in atherosclerosis-prone apoE–/– mice 
[39]. Lack of FGF21 in these mice led to marked exacerbation 
of atherosclerotic plaque formation and reduced lifespan [39]. 
Mechanistic studies showed that, in addition to acting through 
adiponectin-dependent mechanisms which inhibit local vascular 
inflammation and neointima formation [39], FGF21 attenuates 
hypercholesterolemia by suppressing the activity of hepatic ste-
rol regulatory element-binding protein-2 and reducing choles-
terol synthesis [39]. Hepatic deficiency of β-klotho largely com-
promised the cholesterol-lowering effects of FGF21, for which 
FGFR2 was responsible [39]. In line with this, FGF21 suppress-
es the expression of stearoyl-coenzyme A (CoA) denaturase 1 
and 3-hydroxy-3methylglutaryl-CoA reductase in the liver in 
mice, which are involved in lipogenesis and cholesterol synthe-
sis respectively [40]. Therefore, the liver appears to be a major 
target of FGF21 in suppressing cholesterol and lipid levels. The 
lipid-lowering effects of FGF21 have been consistently demon-
strated in mice [18,41]. In diabetic monkeys, the administration 
of recombinant FGF21 does-dependently improved the blood 
lipid profile, as indicated by significantly reduced triglyceride, 
total cholesterol, LDL-C and very low density lipoprotein cho-
lesterol (VLDL-C), as well as increased HDL-C [42].
THERAPEUTIC POTENTIAL OF FGF21 
MIMETICS IN TREATING 
ATHEROSCLEROSIS
FGF21 mimetics can be roughly categorized into FGF21 ana-
logues and activating antibodies against FGFR/β-klotho. A 
number of animal [43-50] and human [51,52] studies have 
Table 2. Associations between FGF21 and Cardiovascular Diseases
CV end-point Result Reference
CV mortality Elevated serum FGF21 predicted combined morbidity and mortality in T2DM [27]
Total CV outcomes Elevated plasma FGF21 [21]
CHD Elevated serum FGF21 [22]
Carotid artery IMT Elevated serum FGF21 [23,24]
Arterial stiffness Brachial-ankle pulse wave velocity independently associated with serum FGF21 [26]
LEAD Elevated serum FGF21 [25]
FGF21, fibroblast growth factor 21; CV, cardiovascular; T2DM, type 2 diabetes mellitus; CHD, coronary heart disease; IMT, intima-media thickness; 
LEAD, lower extremity atherosclerotic disease. 
Table 3. Selected List of FGF21 Mimetics with Reported Lipid-Lowering Properties
Name Company Structural feature/Modification Lipid-lowering effect Reference
R1MAb Genentech β-Klotho-independent agonistic mAb 
against FGFR1b/c
↓ Hepatic TC & TG; 
   ↓ serum TC & NEFA (db/db mice)
[43]
Fc-FGF21(RG) Amgen L98R (↓ aggregation); 
P171G (↓ proteolysis); 
Fusion to Fc (↑ half-life)
↓ Serum TC & TG (DIO mice)
↓ Fasted serum TG (DIO monkeys)
[45]
LY2405319 Lilly L118C, A134C (disulphide bridge); 
S167A (↓ glycosylation in yeast); 
HPIP deletion (↓ proteolysis)
↓ Serum TG, TC & VLDL-C; 
   ↑ serum HDL-C (diabetic rhesus monkeys)
↓ Serum TG, TC, LDL-C & VLDL-C; 
   ↑ serum HDL-C (humans)
[48,51]
PF-05231023 Pfizer A129C (linkage to CVX-200);
CVX-200 conjugation (↑ half-life)
↓ Serum TG & VLDL-C; 
   ↑ serum HDL-C (obese cynomolgus monkeys)
↓ Serum TG, TC & LDL-C; 
   ↑ serum HDL-C (humans)
[53]
FGF21, fibroblast growth factor 21; R1MAb, FGFR1 with monoclonal anti-FGFR1 antibody; mAb, monoclonal antibody; FGFR1, FGF receptor 1; TC, 
total cholesterol; TG, triglyceride; NEFA, non-esterified fatty acid; Fc, antibody constant domain; DIO, diet-induced obesity; HPIP, histidine-proline-
isoleucine-proline; VLDL-C, very low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein 
cholesterol; CVX, CovX-body. 
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shown superior efficacy of FGF21 mimetics compared with na-
tive FGF21 in terms of half-life and resistance against aggrega-
tion and in vivo degradation. While most of these studies fo-
cused on improving insulin sensitivity and β-cell function in 
obesity and diabetes, some studies reported encouraging out-
comes in combating proatherosclerotic lipid profiles (Table 3).
R1MAb (monoclonal anti-FGFR1 antibody), a phage-derived 
agonistic monoclonal antibody specific for FGFR1 with nano-
molar affinity, was the first FGF21 mimetic identified to possess 
lipid-lowering properties at least in mice [43]. Administration of 
R1MAb to genetically diabetic db/db mice caused significant 
reduction in hepatic cholesterol and triglyceride, as well as se-
rum cholesterol and non-esterified fatty acids [43]. The benefi-
cial effects conferred by R1MAb were similar to those by native 
FGF21, which depend on normal functioning of adipose tissues 
[43]. Remarkably, a single injection of this monoclonal anti-
body exhibited sustained activity for more than 30 days [43]. 
Antibody-based FGF21 mimicry is therefore a promising option 
for long-term treatment of dyslipidemia and atherosclerosis.
Veniant et al. [45] generated a long-acting FGF21, Fc (anti-
body constant domain)-FGF21(RG), by fusing an Fc motif to a 
recombinant human FGF21 containing two structurally-stabiliz-
ing mutations. In obese mice, Fc-FGF21(RG) displayed marked-
ly improved pharmacokinetics compared with native FGF21, as 
its effects on reducing serum cholesterol and triglyceride, when 
administered at 2.3 mg/kg every 5 days, was comparable to that 
of human recombinant FGF21 (hrFGF21) administered twice 
daily at 1.0 mg/kg [45]. Further, Fc-FGF21(RG) significantly re-
duced serum triglyceride in fasted or fed rhesus monkeys [45]. It 
was, however, surprising that neither Fc-FGF21(RG) nor hrF-
GF21 reduced cholesterol in these obese monkeys, which was 
demonstrated previously by Kharitonenkov et al. [42].
LY2405319 is a long-acting FGF21 which has an additional 
stabilizing disulphide bond and lacks the proteolysis-prone N-
terminus [48]. The lipid-lowering properties of LY2405319 
were more comprehensively investigated in both diabetic rhesus 
monkeys [48] and humans [51]. Daily administration at 3 mg/
kg was sufficient for a significant improvement in circulating 
lipids in rhesus monkeys as soon as 2 weeks into treatment [48]. 
Levels of triglyceride, total cholesterol and VLDL-C were mark-
edly reduced, while that of HDL-C was elevated significantly. 
LDL-C was modestly reduced by LY2405319 treatment [48]. 
Similarly, a randomized, placebo-controlled and double-blinded 
trial involving obese patients with type 2 diabetes showed posi-
tive and rapid effects on these lipids with daily LY2405319 
treatment, being observable by as early as 2 days, and reaching 
maximal effect within 1 to 3 weeks, except that a higher dose 
(10 or 20 mg/kg) was required to have significant impact on to-
tal cholesterol and LDL-C levels [51].
Another long-acting FGF21, PF-05231023, was engineered 
by site-specific covalent conjugation of two hrFGF21 molecules 
to the Fab motif of a scaffold antibody, CVX-200 [49]. This 
complex was shown to have up to 70-fold increase in half-life 
compared with native FGF21 [49]. Pharmacokinetic and phar-
macodynamics evaluation also suggested a bi-weekly intrave-
nous (IV) delivery regimen in humans [52]. A subsequent study 
in obese cynomolgus monkeys showed that bi-weekly IV ad-
ministration at 10 mg/kg significantly improved the lipid pro-
file. Specifically, triglyceride was reduced by around 70% by 8 
days, whereas for lipoproteins, there was a 74% reduction from 
baseline in the VLDL-C fraction and a 27% increase in the 
HDL-C fraction after 4 weeks [53]. Consistent with previous 
reports [48,52], the LDL-C fraction was less sensitive to FGF21 
mimetics as no significant difference was observed between ve-
hicle and treatment groups [53]. PF-05231023 also exhibited 
additive lipid-lowering effects in overweight or obese humans 
with type 2 diabetes who were on stable dose of metformin in a 
phase 1b trial [53]. Bi-weekly IV dosages at 100 and 140 mg/kg 
effectively reduced triglyceride, total cholesterol, and LDL-C, 
and increased HDL-C by as early as day 8 [53]. Together, these 
clinical studies demonstrate high therapeutic potential of FGF21 
mimetics in the treatment of atherosclerosis through reversing 
dyslipidemia, in addition to its beneficial effects on other condi-
tions which promote atherosclerosis including obesity [51,53], 
hyperinsulinemia [51], and hypoadiponectinemia [51,53].
It is, however, noteworthy that the administration of FGF21 
mimetics in humans was not without adverse events [51-53]. 
FGF21 has been discovered for less than two decades, and its 
functional role in many physiological aspects is still poorly un-
derstood. More comprehensive functional characterization of 
FGF21 in different organs and physiological systems is needed 
to ensure minimal harm is introduced during treatments. Its in-
volvement in bone health, for instance, remains unclear [54,55]. 
Furthermore, novel approaches to sensitize FGF21 signaling 
through modulation of FGFR/β-klotho complex or downstream 
players should be explored. The introduction of standardized 
guidelines for FGF21 mimetics dosing will also be beneficial 
for rigorous evaluation of FGF21-targeted therapies.
CONCLUSIONS
FGF21 has recently emerged to be a major regulator of glucose 
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and lipid metabolism that exerts pleiotropic effects in multiple 
target organs, including the liver and adipose tissue. Although 
most of the early studies on FGF21 focused on glucose metabo-
lism and insulin actions, recent evidence strongly suggests a 
critical role for FGF21 in modulating lipid and lipoprotein me-
tabolism. FGF21 has been identified to be a predictive and 
prognostic biomarker of atherosclerotic risk factors and cardio-
vascular diseases. The therapeutic potential of FGF21-targeting 
approaches in treating atherosclerosis has been demonstrated by 
studies on several FGF21 mimetics, which possess superior 
pharmacological features compared with native FGF21 and ex-
hibit prominent lipid-lowering effects in both animals and hu-
mans. Despite these initial favorable outcomes of FGF21 mi-
metics-based therapies, the evidence for their long-term effica-
cy, optimal therapeutic window and adverse side effects is rela-
tively limited. Whether FGF21 mimetics can be routinely ap-
plied in treatment for atherosclerosis requires further investiga-
tions.
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